Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
1. | Registration Statement (Form S-3 No. 333-239780) of Marinus Pharmaceuticals, Inc.; |
2. | Registration Statement (Form S-3 No. 333-237903) of Marinus Pharmaceuticals, Inc.; |
3. | Registration Statement (Form S-8 No. 333-258677) pertaining to the Marinus Pharmaceuticals, Inc. 2014 Equity Incentive Plan, as amended, and Individual Nonqualified Stock Option Awards; |
4. | Registration Statement (Form S-8 No. 333-239785) pertaining to the Marinus Pharmaceuticals, Inc. 2014 Equity Incentive Plan, as amended, and Individual Nonqualified Stock Option Awards; |
5. | Registration Statement (Form S-8 No. 333-233131) pertaining to the Marinus Pharmaceuticals, Inc. 2014 Equity Incentive Plan, as amended, and Individual Nonqualified Stock Option Awards; |
6. | Registration Statement (Form S-8 No. 333-219613) pertaining to the Marinus Pharmaceuticals, Inc. 2014 Equity Incentive Plan; |
7. | Registration Statement (Form S-8 No. 333-200701) pertaining to the Marinus Pharmaceuticals, Inc. 2014 Equity Incentive Plan; and |
8. | Registration Statement (Form S-8 No. 333-265865) pertaining to the Marinus Pharmaceuticals, Inc. 2014 Equity Incentive Plan, as amended, Individual Nonqualified Stock Option Awards, and Individual Restricted Stock Units; |
of our report dated March 9, 2023, with respect to the consolidated financial statements of Marinus Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Marinus Pharmaceuticals, Inc. for the year ended December 31, 2022.
/s/ Ernst & Young LLP
Philadelphia, PA
March 9, 2023